SG11202103033WA - Compositions and methods for the treatment of presbyopia - Google Patents
Compositions and methods for the treatment of presbyopiaInfo
- Publication number
- SG11202103033WA SG11202103033WA SG11202103033WA SG11202103033WA SG11202103033WA SG 11202103033W A SG11202103033W A SG 11202103033WA SG 11202103033W A SG11202103033W A SG 11202103033WA SG 11202103033W A SG11202103033W A SG 11202103033WA SG 11202103033W A SG11202103033W A SG 11202103033WA
- Authority
- SG
- Singapore
- Prior art keywords
- presbyopia
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1412—Containers with closing means, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743720P | 2018-10-10 | 2018-10-10 | |
| PCT/US2019/055116 WO2020076769A1 (fr) | 2018-10-10 | 2019-10-08 | Compositions et procédés pour le traitement de la presbytie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103033WA true SG11202103033WA (en) | 2021-04-29 |
Family
ID=70161531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103033WA SG11202103033WA (en) | 2018-10-10 | 2019-10-08 | Compositions and methods for the treatment of presbyopia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10836760B2 (fr) |
| EP (1) | EP3863630A4 (fr) |
| JP (1) | JP2022504746A (fr) |
| KR (1) | KR20210076941A (fr) |
| CN (1) | CN113518620A (fr) |
| AU (1) | AU2019357979A1 (fr) |
| BR (1) | BR112021006618B1 (fr) |
| CA (1) | CA3114204A1 (fr) |
| MA (1) | MA53873A (fr) |
| MX (1) | MX2021004183A (fr) |
| SG (1) | SG11202103033WA (fr) |
| WO (1) | WO2020076769A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021222525A1 (fr) * | 2020-04-30 | 2021-11-04 | Eye Therapies, Llc | Compositions de brimonidine et procédés d'utilisation |
| CA3195422A1 (fr) * | 2020-10-13 | 2022-04-21 | Gerald Horn | Compositions et procedes pour des medicaments ophtalmiques stables au stockage |
| WO2022232205A1 (fr) * | 2021-04-28 | 2022-11-03 | Lenz Therapeutics, Inc. | Procédé de réduction de douleur de sourcil |
| CN116459251A (zh) * | 2022-01-18 | 2023-07-21 | 苏州普乐康医药科技有限公司 | 一种含西维美林的眼用制剂及其制备方法和应用 |
| TW202329958A (zh) * | 2022-01-25 | 2023-08-01 | 張金明 | 西維美林水溶液組合物和使用方法 |
| US20230310380A1 (en) * | 2022-04-05 | 2023-10-05 | Alan Neil Glazier | Methods, devices, and systems for treating lens protein aggregation diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994001096A1 (fr) * | 1992-07-02 | 1994-01-20 | Telor Ophthalmic Pharmaceuticals, Inc. | Procedes et produits permettant de traiter la presbytie |
| US20090297566A1 (en) * | 2004-12-27 | 2009-12-03 | Brinkman Kyle R | Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions |
| US20190038609A1 (en) * | 2013-08-28 | 2019-02-07 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) * | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US10307408B2 (en) * | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
-
2019
- 2019-10-08 MA MA053873A patent/MA53873A/fr unknown
- 2019-10-08 BR BR112021006618-7A patent/BR112021006618B1/pt active IP Right Grant
- 2019-10-08 MX MX2021004183A patent/MX2021004183A/es unknown
- 2019-10-08 CA CA3114204A patent/CA3114204A1/fr active Pending
- 2019-10-08 AU AU2019357979A patent/AU2019357979A1/en active Pending
- 2019-10-08 SG SG11202103033WA patent/SG11202103033WA/en unknown
- 2019-10-08 EP EP19871827.2A patent/EP3863630A4/fr active Pending
- 2019-10-08 CN CN201980067359.1A patent/CN113518620A/zh active Pending
- 2019-10-08 JP JP2021519886A patent/JP2022504746A/ja active Pending
- 2019-10-08 WO PCT/US2019/055116 patent/WO2020076769A1/fr active Application Filing
- 2019-10-08 US US16/595,789 patent/US10836760B2/en active Active
- 2019-10-08 KR KR1020217014044A patent/KR20210076941A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA53873A (fr) | 2022-01-19 |
| US20200115377A1 (en) | 2020-04-16 |
| CN113518620A (zh) | 2021-10-19 |
| CA3114204A1 (fr) | 2020-04-16 |
| MX2021004183A (es) | 2021-10-26 |
| WO2020076769A1 (fr) | 2020-04-16 |
| BR112021006618A2 (pt) | 2021-07-06 |
| BR112021006618B1 (pt) | 2022-09-27 |
| EP3863630A4 (fr) | 2022-06-29 |
| US10836760B2 (en) | 2020-11-17 |
| EP3863630A1 (fr) | 2021-08-18 |
| JP2022504746A (ja) | 2022-01-13 |
| KR20210076941A (ko) | 2021-06-24 |
| AU2019357979A1 (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268406A (en) | Preparations and methods for treating hemoglobin diseases | |
| EP3675882A4 (fr) | Methodes et compositions pour le traitement de troubles associés au microbiome | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| IL275626A (en) | Preparations and methods for surface treatment | |
| ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| EP3833340A4 (fr) | Compositions et procédés de traitement de la presbytie | |
| IL275182A (en) | Preparations and methods for the treatment of metabolic conditions | |
| EP3429584A4 (fr) | Compositions et méthodes de traitement de la presbytie | |
| IL272937A (en) | Preparations and methods for the treatment of diseases involving fibrosis | |
| IL262508A (en) | Methods and preparations for the treatment of degenerate bone | |
| ZA202101342B (en) | Compositions and methods for treating the eye | |
| IL287796A (en) | Preparations and methods for the treatment of diseases mediated by ATPase | |
| IL272121A (en) | Preparation and methods for the treatment of myopia | |
| EP3368048A4 (fr) | Méthodes et compositions pour le traitement de l'amyloïdose | |
| SG11202104053TA (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| SG11201809811VA (en) | Compositions and methods for treatment of inflammation or infection of the eye | |
| IL264977A (en) | Methods and preparations for the treatment of melanoma | |
| ZA202101361B (en) | Compositions and methods for treating the eye | |
| ZA202101360B (en) | Compositions and methods for treating the eye | |
| IL280348A (en) | Surface treatment compositions and methods | |
| IL278978A (en) | Preparations and methods for treating eczema | |
| IL272147A (en) | Methods and preparations for the treatment of cancer | |
| IL280262A (en) | Compositions and methods for treating cancer | |
| GB201810923D0 (en) | Compositions and method of treatment |